178 related articles for article (PubMed ID: 12559800)
1. Carrier-dependent specificity of antibodies to a conserved peptide determinant of gp120.
Karle S; Nishiyama Y; Taguchi H; Zhou YX; Luo J; Planque S; Hanson C; Paul S
Vaccine; 2003 Mar; 21(11-12):1213-8. PubMed ID: 12559800
[TBL] [Abstract][Full Text] [Related]
2. Epitope specificity, antibody-dependent cellular cytotoxicity, and neutralizing activity of antibodies to human immunodeficiency virus type 1 in autoimmune MRL/lpr mice.
Lombardi V; Placido R; Scarlatti G; Romiti ML; Mattei M; Mariani F; Poccia F; Rossi P; Colizzi V
J Infect Dis; 1993 Jun; 167(6):1267-73. PubMed ID: 7684755
[TBL] [Abstract][Full Text] [Related]
3. Epitope specificity of anti-HIV antibodies in human and murine autoimmune diseases.
Fraziano M; Montesano C; Lombardi VR; Sammarco I; De Pisa F; Mattei M; Valesini G; Pittoni V; Colizzi V
AIDS Res Hum Retroviruses; 1996 Apr; 12(6):491-6. PubMed ID: 8679304
[TBL] [Abstract][Full Text] [Related]
4. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
5. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
[TBL] [Abstract][Full Text] [Related]
6. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
[TBL] [Abstract][Full Text] [Related]
7. Candidate multi-epitope vaccines in aluminium adjuvant induce high levels of antibodies with predefined multi-epitope specificity against HIV-1.
Ding J; Lu Y; Chen Y
FEMS Immunol Med Microbiol; 2000 Oct; 29(2):123-7. PubMed ID: 11024351
[TBL] [Abstract][Full Text] [Related]
8. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
Staats HF; Nichols WG; Palker TJ
J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
[TBL] [Abstract][Full Text] [Related]
9. Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1(SF2) p17) and peptide segments of human beta-2-microglobulin or MHC II beta chain.
Zimmerman DH; Lloyd JP; Heisey D; Winship MD; Siwek M; Talor E; Sarin PS
Vaccine; 2001 Sep; 19(32):4750-9. PubMed ID: 11535326
[TBL] [Abstract][Full Text] [Related]
10. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.
Neurath AR; Strick N; Lee ES
J Gen Virol; 1990 Jan; 71 ( Pt 1)():85-95. PubMed ID: 1689372
[TBL] [Abstract][Full Text] [Related]
11. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
[TBL] [Abstract][Full Text] [Related]
12. Binding of glycoprotein 120 and peptides from the HIV-1 envelope by autoantibodies in mice with experimentally induced systemic lupus erythematosus and in patients with the disease.
Bermas BL; Petri M; Berzofsky JA; Waisman A; Shearer GM; Mozes E
AIDS Res Hum Retroviruses; 1994 Sep; 10(9):1071-7. PubMed ID: 7826694
[TBL] [Abstract][Full Text] [Related]
13. Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120.
Boudet F; Girard M; Theze J; Zouali M
Int Immunol; 1992 Feb; 4(2):283-94. PubMed ID: 1377948
[TBL] [Abstract][Full Text] [Related]
14. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
15. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.
Ota A; Tanaka-Taya K; Ueda S
Hybridoma; 1999 Apr; 18(2):149-57. PubMed ID: 10380014
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1.
Lu Y; Xiao Y; Ding J; Dierich M; Chen YH
Int Arch Allergy Immunol; 2000 Jan; 121(1):80-4. PubMed ID: 10686512
[TBL] [Abstract][Full Text] [Related]
17. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
18. Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine.
Planque SA; Mitsuda Y; Nishiyama Y; Karle S; Boivin S; Salas M; Morris MK; Hara M; Liao G; Massey RJ; Hanson CV; Paul S
J Immunol; 2012 Dec; 189(11):5367-81. PubMed ID: 23089396
[TBL] [Abstract][Full Text] [Related]
19. Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development.
May RJ; Beenhouwer DO; Scharff MD
J Immunol; 2003 Nov; 171(9):4905-12. PubMed ID: 14568972
[TBL] [Abstract][Full Text] [Related]
20. Dual specificity of a monoclonal anti-idiotypic antibody for HIV-1 neutralizing monoclonals 110.3 and 110.4 as well as the V3 loop of gp120.
Connelly RJ; Kahn M; Blake J; Haffar OK; Thomas EK
Virology; 1994 Dec; 205(2):554-7. PubMed ID: 7526543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]